Mixed allele malaria vaccines: host protection and within-host selection
- PMID: 18804509
- PMCID: PMC2674600
- DOI: 10.1016/j.vaccine.2008.09.004
Mixed allele malaria vaccines: host protection and within-host selection
Abstract
Malaria parasites are frequently polymorphic at the antigenic targets of many candidate vaccines, presumably as a consequence of selection pressure from protective immune responses. Conventional wisdom is therefore that vaccines directed against a single variant could select for non-target variants, rendering the vaccine useless. Many people have argued that a solution is to develop vaccines containing the products of more than one variant of the target. However, we are unaware of any evidence that multi-allele vaccines better protect hosts against parasites or morbidity. Moreover, selection of antigen-variants is not the only evolution that could occur in response to vaccination. Increased virulence could also be favored if more aggressive strains are less well controlled by vaccine-induced immunity. Virulence and antigenic identity have been confounded in all studies so far, and so we do not know formally from any animal or human studies whether vaccine failure has been due to evasion of protective responses by variants at target epitopes, or whether vaccines are just less good at protecting against more aggressive strains. Using the rodent malaria model Plasmodium chabaudi and recombinant apical membrane antigen-1 (AMA-1), we tested whether a bi-allelic vaccine afforded greater protection from parasite infection and morbidity than did vaccination with the component alleles alone. We also tested the effect of mono- and bi-allelic vaccination on within-host selection of mixed P. chabaudi infections, and whether parasite virulence mediates pathogen titres in immunized hosts. We found that vaccination with the bi-allelic AMA-1 formulation did not afford the host greater protection from parasite infection or morbidity than did mono-allelic AMA-1 immunization. Mono-allelic immunization increased the frequency of heterologous clones in mixed clone infections. There was no evidence that any type of immunization regime favored virulence. A single AMA-1 variant is a component of candidate malaria vaccines current in human trials; our results suggest that adding extra AMA-1 alleles to these vaccines would not confer clinical benefits, but that that mono-allelic vaccines could alter AMA-1 allele frequencies in natural populations.
Figures





Similar articles
-
The evolutionary consequences of blood-stage vaccination on the rodent malaria Plasmodium chabaudi.PLoS Biol. 2012;10(7):e1001368. doi: 10.1371/journal.pbio.1001368. Epub 2012 Jul 31. PLoS Biol. 2012. PMID: 22870063 Free PMC article.
-
Protection against Plasmodium chabaudi malaria induced by immunization with apical membrane antigen 1 and merozoite surface protein 1 in the absence of gamma interferon or interleukin-4.Infect Immun. 2004 Oct;72(10):5605-12. doi: 10.1128/IAI.72.10.5605-5612.2004. Infect Immun. 2004. PMID: 15385457 Free PMC article.
-
CD4+ T cells acting independently of antibody contribute to protective immunity to Plasmodium chabaudi infection after apical membrane antigen 1 immunization.J Immunol. 2000 Jul 1;165(1):389-96. doi: 10.4049/jimmunol.165.1.389. J Immunol. 2000. PMID: 10861076
-
Designing malaria vaccines to circumvent antigen variability.Vaccine. 2015 Dec 22;33(52):7506-12. doi: 10.1016/j.vaccine.2015.09.110. Epub 2015 Nov 1. Vaccine. 2015. PMID: 26475447 Free PMC article. Review.
-
Apical membrane antigen 1: a malaria vaccine candidate in review.Trends Parasitol. 2008 Feb;24(2):74-84. doi: 10.1016/j.pt.2007.12.002. Epub 2008 Jan 15. Trends Parasitol. 2008. PMID: 18226584 Review.
Cited by
-
Stress and sex in malaria parasites: Why does commitment vary?Evol Med Public Health. 2013 Jan;2013(1):135-47. doi: 10.1093/emph/eot011. Epub 2013 Jun 4. Evol Med Public Health. 2013. PMID: 24481194 Free PMC article.
-
Humoral immune response to mixed PfAMA1 alleles; multivalent PfAMA1 vaccines induce broad specificity.PLoS One. 2009 Dec 1;4(12):e8110. doi: 10.1371/journal.pone.0008110. PLoS One. 2009. PMID: 19956619 Free PMC article.
-
The evolutionary consequences of blood-stage vaccination on the rodent malaria Plasmodium chabaudi.PLoS Biol. 2012;10(7):e1001368. doi: 10.1371/journal.pbio.1001368. Epub 2012 Jul 31. PLoS Biol. 2012. PMID: 22870063 Free PMC article.
-
Generation of humoral immune responses to multi-allele PfAMA1 vaccines; effect of adjuvant and number of component alleles on the breadth of response.PLoS One. 2010 Nov 3;5(11):e15391. doi: 10.1371/journal.pone.0015391. PLoS One. 2010. PMID: 21082025 Free PMC article.
-
Immunization with different PfAMA1 alleles in sequence induces clonal imprint humoral responses that are similar to responses induced by the same alleles as a vaccine cocktail in rabbits.Malar J. 2011 Feb 14;10:40. doi: 10.1186/1475-2875-10-40. Malar J. 2011. PMID: 21320299 Free PMC article.
References
-
- Richie T.L., Saul A. Progress and challenges for malaria vaccines. Nature. 2002;415:694–701. - PubMed
-
- Anders R.F., Crewther P.E., Edwards S., Margetts M., Matthew M.L.S.M., Pollock B. Immunisation with recombinant AMA-1 protects mice against infection with Plasmodium chabaudi. Vaccine. 1998;16:240–247. - PubMed
-
- Mendis K.N., David P.H., Carter R. Anigenic polymorphism in malaria: is it an important mechanism for immune evasion? Immunol Today. 1991;12:A34–A37. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical